Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

1,173 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT05156905 2024-10-09

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

6 enrolled

Genitourinary

Prostatic Neoplasms

NCT03230734 2024-09-27

RAPSON

Phase 2 Active not recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT02649855 2024-08-06

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Phase 2 Completed

74 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT01446731 2024-07-03

Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer

Phase 2 Completed

43 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT03066154 2024-06-03

DOP

Phase 1 Terminated

24 enrolled

Genitourinary

Prostatic Neoplasms

NCT02453009 2024-05-30

CHEIRON

Phase 2 Completed

246 enrolled

Genitourinary

Prostatic Neoplasms

NCT03358563 2024-05-03

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Phase EARLY_PHASE1 Completed

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT03700099 2024-04-15

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

Phase 2 Active not recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT03311555 2024-03-19

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Phase 2 Completed

39 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT05627752 2024-02-28

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Phase 2/3 Unknown

120 enrolled

Genitourinary

Prostatic Neoplasms

NCT06282588 2024-02-28

THUNDER

Phase 2/3 Recruiting

493 enrolled

Genitourinary

Prostatic Neoplasms

NCT00099086 2024-01-31

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 1 Completed

20 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

MK-2400-001

MEVPRO-1

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

OPTION-DDR

rechARge

CheckMate 9KD

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

TRIPLE-SWITCH

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

Lutécio

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

CONVERT-HB1

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

KEYNOTE-921

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

HS-10502

CheckMate 7DX

PKUFH-GS5

CABPOSTAAT

PRESIDE

CAPItello280

GUNS

IVY

PEACE1

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

RAPSON

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

KEYNOTE-921

Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer

DOP

CHEIRON

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

THUNDER

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer